Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer - Expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy

Journal of Gene Medicine

Volumn 8, Issue 11, 2006, Pages 1329-1340

  Kanai, Ryuichi ^a   Eguchi, Keisuke ^a   Takahashi, Miwa ^a   Goldman, Steven ^b   Okano, Hideyuki ^a   Kawase, Takeshi ^a   Yazaki, Takahito ^a  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

34.5 gene; Gene therapy; Musashi1; Non small cell lung cancer; Oncolytic herpes virus vector G207

Indexed keywords

GREEN FLUORESCENT PROTEIN; MARKER; PROTEIN MUSASHI1; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HELPER VIRUS; HERPESVIRUS VECTOR; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; ONCOLYTIC VIRUS; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MODEL; TUMOR VOLUME; VIRAL GENE THERAPY; VIROGENESIS; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NERVE TISSUE PROTEINS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; RNA, NEOPLASM; RNA-BINDING PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; HERPES; HERPESVIRIDAE;

EID: 33751231415     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.965     Document Type: Article

References (58)

1. Cancer Facts and Figures, American Cancer Society: Atlanta, GA, 2005.
2. Nesbitt LC, Putnam JB Jr, Walsh GL, et al. Survival in early stage non-small cell lung cancer. Ann Thorac Surg 1995; 60: 466-472.
3. Jett JR. Current treatment of unresectable lung cancer. Mayo Clin Proc 1993; 68: 603-611.
4. Elias A. Chemotherapy and radiotherapy for regionally advanced non-small-cell lung cancer. Chest 1993; 103(4 Suppl.): 362S-366S.
5. Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
6. Boviatsis EJ, Chase MX, Wei T, et al. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther 1994; 5:183-191.
7. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885. DOI: 10. 1038/78638.
8. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859-866.
9. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phasel trial. Gene Ther 2000; 7:867-874.
10. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8: 89-98.
11. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787. DOI: 10. 1038/89901.
12. -) herpes simplex virus HSV1716 following intratumoral injection into human malignant glioma: a proof of principle study. Gene Ther 2002; 9:398-406.
13. Detta A, Harland J, Hanif I, et al. Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumors. J Gene Med 2003; 5: 681-689. DOI: 10. 1002/jgm.396.
14. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
15. Yazaki T, Manz HJ, Rabkin SD, et al. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 1: 4752-4756.
16. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-2185.
17. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther 2000; 11: 1683-1693.
18. Walker JR, McGeagh KG, Sundaresan P, et al. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207 Hum Gene Ther 1999; 10: 2237-2243.
19. Toyoizumi T, Mick R, Abbas AE, et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV1716) in human non-small cell lung cancer. Hum Gene Ther 1999; 10: 3013-3029.
20. Coukos G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5: 1523-1537.
21. Carroll NM, Chiocca EA, Takahashi K, et al. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224: 323-329, discussion 329-330.
22. Pawlik TM, Nakamura H, Yoon S S, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60: 2790-2795.
23. Sundaresan P, Hunter WD, Martuza RL, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000; 74: 3832-3841.
24. Todo T, Feigenbaum F, Rabkin SD, et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2000; 2: 588-595. DOI: 10. 1006/mthe.2000.0200.
25. Varghese S, Newsome JT, Rabkin SD, et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001; 12: 999-1010.
26. Kramm CM, Chase M, Herrlinger U, et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8: 2057-2068.
27. Okano H, Kawahara H, Toriya M, et al. Function of RNA binding protein Musashi-1 in stem cells. Exp Cell Res 2005; 306: 349-356.
28. Okano H, Imai T, Okabe M. Musashi: a translational regulator of cell fates. J. Cell Sci 2002; 115: 1355-1359.
29. Nakamura M, Okano H, Blendy JA, et al. Musashi1, a neural RNA-binding protein required for Drospohila adult external sensory organ development. Neuron 1994; 13: 67-81.
30. Sakakibara S, Imai T, Hamaguchi K, et al. Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev Biol 1996; 176: 230-242.
31. Good P, Yoda A, Sakakibara S, et al. The human Musashi homolog 1 (MSI1) gene encoding the homologue of Musashi/Nrp-1, a neural RNA-binding protein putatively expressed in CNS stem cells and neural progenitor cells. Genomics 1998; 52: 382-384.
32. Kaneko Y, Sakakibara S, Imai T, et al. Musashi1: an evolutionally conserved marker for CNS progenitor cells including neural stem cells. Dev Neurosci 2000; 22: 139-153.
33. Kanemura Y, Mori K, Sakakibara S, et al. Musashi1, an evolutionally conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation 2001; 68: 141-152.
34. Toda M, Iizuka Y, Yu W, et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. GLIA 2001; 34: 1-7. DOI: 10. 1002/ glia.1034.
35. Potten CS, Booth C, Tudor GL, et al. Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation 2003; 71: 28-41.
36. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of IgF2 alters intestinal maturation and tumorigenesis in mice. Science 2005; 307: 1976-1978.
37. Shu H, Saito T, Watanabe H, et al. Expression of the Musashi1 gene encoding the RNA-binding protein in human hepatoma cell lines. Biochem Biophys Res Commun 2002; 293: 150-154. DOI: 10. 1016/ SO006-291x(02)00175-4.
38. Kanai R, Tomita. H, Shinoda A, et al. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of γ34.5-mediated virulence. Gene Ther 2006;13:106-116.
39. Keyoung HM, Roy NS, Benraiss A, et al. High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain. Nat Biotechnol 2001; 19: 843-850. DOI: 10. 1038/ nbt0901-843.
40. Kaplitt MG, Pfaus JG, Kleopoulos SP, et al. Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol Cell Neurosci 1991; 2: 320-330.
41. Yazaki T, Martuza RL, Rabkin SD. Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration. Mol Brain Res 1996;43:311-320.
42. Mckie EA, MacLean AR, Lewis AD, et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS turnouts - evaluation of a potentially effective clinical therapy. Br J Cancer 1996; 74: 745-752.
43. Fu X, Tao L, Jin A, et al. Expression of a fusogenic glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003; 7: 748-754, DOI: 10.1016/S1525-0016(03)00092-3.
44. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62: 2306-2312.
45. 134.5 herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the α47 gene. J Virol 1997; 71: 6049-6054.
46. Taneja S, MacGregor J, Markus S, et al. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001; 98: 8804-8808. DOI: 10. 1073/ pnas.161011798.
47. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001; 98: 6396-6401. DOI: 10. 1073/ pnas.101136398.
48. Pyles RB, Warnick RE, Chalk CL, et al. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 1997; 8: 533-544.
49. Laquerre S, Anderson DB, Stolz DB, et al. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol 1998; 72: 9683-9697.
50. Miyatake S-I, Tani S, Feigenbaum F, et al. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 1999; 6: 564-572.
51. Chung RY, Saeki Y, Chiocca EA. B-myb promoter retargeting of herpes simplex virus γ34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 1999; 73: 7556-7564.
52. Kambara H, Okano H, Chiocca EA, et al. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005; 65: 2832-2839.
53. Akasaka Y, Saikawa Y, Fujita K, et al. Expression of a candidate marker for progenitor cells, Musashi-1, in the proliferative regions of human antrum and its decreased expression in intestinal metaplasia. Histopathology 2005; 47: 348-356.
54. Clarke RB, Spence K, Anderson E, et al, A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev. Biol. 2005; 277: 443-456.
55. Imai T. Tokunaga A, Yoshida T, et al. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol 2001; 21: 3888-3900. DOI: 10. 1128/MCB.21.12.3888-3900.2001.
56. γ134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA 1992; 89: 3266-3270.
57. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001; 3: 745-750. DOI: 10.1038/35087061.
58. Ikeda K, Wakimoto H, Ichikawa T, et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000; 74: 4765-4775.